Atypical presentations of conditions make identifying source of Fever of Unknown Origin (FUO) challenging. Incidence of hepatic abscesses (HA) in the pediatric population in the U.S. is 25 per 100,000 admissions. Most cases occur in children with predisposing factors such as appendicitis or immunocompromised state.
SARS-CoV-2 superinfection can masquerade as COVID-19 flare or non-infectious ARDS. No method of diagnosis of bacterial pneumonia exists for non-intubated patients. Lower respiratory culture results in ~1 week and not all pathogens can be cultured. Differential diagnoses have contradictory treatments. We aimed to compare host transcriptomics of Delta variant versus other variants. We aimed to characterize microbiome of upper and lower airway in patients with COVID-19
• Botswana has a very high HIV-prevalence rate (>20%)
• 75% of HIV-related CM deaths occur in Sub-Saharan Africa
• 1-year survival rate for CM is 35% in Botswana
• HIV is a major risk factor for CM, although the cause of high-incidence of HIV-associated CM is multifactorial
• Epidemiologic investigation used to make policy changes and prevent future spread
• Timely and accurate investigation vital for staff and patient safety
• Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) causes coronavirus disease 2019 (COVID-19), which can range from mild symptoms to death from respiratory failure and multi-organ dysfunction.• Correctional facilities serve as a nidus for infection due to limited space from overcrowding which is further complicated by an increasingly elderly and sick inmate population.• California, which houses nearly 95,000 inmates, has the largest inmate population of any state in the US.• LY-CoV555, also known as bamlanivimab, has been shown to reduce viral load in patients as soon as within one week of administration. • This study reports data on inmate-patients who were offered LY-CoV555 therapy based on the EUA and clinical judgement of providers rounding on COVID patients at one correctional facility. • No data exists on the utilization of LY-CoV555 and outcomes associated with its use in a congregate setting.
